Cardiothoracic & vascular anesthesia
Methylprednisolone Does Not Enhance Paraoxonase 1 Activity During Cardiopulmonary Bypass Surgery—A Randomized, Controlled Clinical Trial
Authors' conclusion
Methylprednisolone does not influence PON1 activity during cardiac surgery on CPB.
Study context
- Population
- Adults undergoing complex cardiac surgery on cardiopulmonary bypass (CPB), University Medical Center Ljubljana, Slovenia, February 2016–December 2017
- Participants
- 40 adults
- Comparison
- Methylprednisolone vs Control
- Methylprednisolonen = 20
- Controln = 20reference
- Primary endpoint
- PON1 activity
- Follow-up
- Until POD 5
Methodological detailsprospective, single-centre
- Prospective
- Single-centre
Primary result
As reported in the abstract
- No significant differences between groups in PON1 activity in any measurement interval
- p > 0.016
Further findings
HDL and LDL
- No significant differences between groups in any measurement interval
- P > 0.016
Inflammatory mediators after surgery
- Lower tumor necrosis factor alpha with methylprednisolone
- P < 0.001
- Lower interleukin-6 with methylprednisolone
- P < 0.001
- Lower C-reactive protein and procalcitonin with methylprednisolone
- P < 0.016
Hemodynamic parameters
- No significant difference between groups
Correlations of PON1 activity
- Positive correlation with lipid status; negative correlation with tumor necrosis factor alpha, interleukin-6 and CPB duration
Original publication
Methylprednisolone Does Not Enhance Paraoxonase 1 Activity During Cardiopulmonary Bypass Surgery—A Randomized, Controlled Clinical Trial. J Cardiothorac Vasc Anesth. Published 28 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →